id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S15201 R62350 |
Cohen (Valproate) (Mixed indications) (Controls unexposed, NOS), 2023 | Nervous system malformation | 1st trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 2.69 [1.56;4.62] | -/2,031 -/4,866,362 | - | 2,031 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12862 R48538 |
Thomas (Valproate) (Controls exposed to Lamotrigine, sick), 2021 | Neural malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.03 [0.05;20.18] C excluded (control group) |
3/341 0/50 | 3 | 341 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12864 R48550 |
Thomas (Valproate) (Controls unexposed, sick), 2021 | Neural malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 7.04 [0.36;136.85] C | 3/341 0/340 | 3 | 341 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9442 R33160 |
Ban (Valproate) (Mixed indications) (Controls exposed to Lamotrigine, sick), 2015 | Nervous system anomaly | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
6.44 [0.31;134.91] C excluded (control group) |
2/214 0/273 | 2 | 214 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9443 R33165 |
Ban (Valproate) (Mixed indications) (Controls unexposed NOS), 2015 | Nervous system anomaly | 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No | 6.60 [1.63;26.67] C | 2/214 367/257,153 | 369 | 214 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9325 R32506 |
Veiby (Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 | Nervous system | throughout pregnancy | population based cohort retrospective | exposed to other treatment, sick | Adjustment: No | 2.51 [0.16;40.18] C | 1/333 1/833 | 2 | 333 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 3.08 [1.88;5.03] | 374 | 2,919 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Valproate) (Mixed indications) (Controls unexposed, NOS; 2: Valproate) (Controls unexposed, sick; 3: Valproate) (Mixed indications) (Controls unexposed NOS; 4: Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 9442, 12862